Abstract
Three patients with metastatic prostatic cancer were treated for 10, 6 and 2 months with the potent LHRH-agonist Buserelin (Hoe 766) as a first-line agent. All showed a fall of elevated prostatic acid phosphatase levels (nearly undetectable after treatment in 2 patients) parallel to plasma testosterone with a relief of complaints after 3–4 weeks of treatment. Two patients had an increment of appetite and body weight. In some patient radiological evidence for objective tumour regression was found by CT scan of the prostate (decrease of 41% in prostate volume), skeletal X-rays and bone scan. In this patient plasma alkaline phosphatase showed a transient increase parallel to disappearance of osteolytic bone lesions (indicating new bone formation) followed by a normalization. It is concluded that LHRH-agonist treatment is effective in patients with metastatic prostatic carcinoma in the absence of serious side-effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
